Literature DB >> 28439399

Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.

Céline Blaye1, Xavier Buy2, Marine Gross-Goupil1, Didier Vincent3, Claire Jamet4, Paul Sargos5, Stéphane Culine6, Guilhem Roubaud7.   

Abstract

Entities:  

Year:  2017        PMID： 28439399      PMCID： PMC5394505          DOI： 10.1177/2042098616682720

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  18 in total

1.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

2.  Reversible posterior leukoencephalopathy syndrome induced by axitinib.

Authors:  Antonin Levy; Lyes Benmoussa; Samy Ammari; Laurence Albiges; Bernard Escudier
Journal:  Clin Genitourin Cancer       Date:  2013-10-14       Impact factor: 2.872

Review 3.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

4.  Posterior reversible encephalopathy syndrome: the endothelial hypotheses.

Authors:  A Marra; M Vargas; P Striano; L Del Guercio; P Buonanno; G Servillo
Journal:  Med Hypotheses       Date:  2014-03-01       Impact factor: 1.538

Review 5.  Renal Toxicities of Targeted Therapies.

Authors:  Anum Abbas; Mohsin M Mirza; Apar Kishor Ganti; Ketki Tendulkar
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

Review 8.  Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Lancet Neurol       Date:  2015-07-13       Impact factor: 44.182

9.  Panitumumab (vectibix).

Authors:  J J Gemmete; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

Review 10.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.